Wealthfront Advisers
IOVA icon

Wealthfront Advisers’s Iovance Biotherapeutics IOVA Stock Holding History

Wealthfront Advisers’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$53.9K Buy
+12,959
New +$49.2K ﹤0.01% 1110
2025
Q4 		– Sell
-15,492
Closed -$33.6K – 1065
2025
Q3 		$33.6K Buy
+15,492
New +$36.6K ﹤0.01% 1003

Other funds holding IOVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Wealthfront Advisers's IOVA Position: Q2 2026 in Review

Wealthfront Advisers opened a new position in Iovance Biotherapeutics (IOVA) in Q2 2026: 12,959 shares worth $53.9K. The stake represents ﹤0.01% of the portfolio and ranks #1110 among its holdings. This is a return to the name: Wealthfront Advisers previously reported a position in IOVA as recently as Q3 2025.

Wealthfront Advisers first reported a position in IOVA in Q3 2025 and has held it in 2 quarters since. 292 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

  • Wealthfront Advisers held 12,959 shares of Iovance Biotherapeutics worth $53.9K as of Q2 2026.
  • Iovance Biotherapeutics was a new Wealthfront Advisers position in Q2 2026.
  • Iovance Biotherapeutics made up ﹤0.01% of Wealthfront Advisers's portfolio in Q2 2026, its #1110 holding.
  • Wealthfront Advisers first reported a position in Iovance Biotherapeutics in Q3 2025 and has held it in 2 quarters since.
  • 292 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on Wealthfront Advisers's 13F filing for Q2 2026, filed 7 Aug 2026.